JP2016513640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513640A5 JP2016513640A5 JP2016500441A JP2016500441A JP2016513640A5 JP 2016513640 A5 JP2016513640 A5 JP 2016513640A5 JP 2016500441 A JP2016500441 A JP 2016500441A JP 2016500441 A JP2016500441 A JP 2016500441A JP 2016513640 A5 JP2016513640 A5 JP 2016513640A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- drug
- sirpα
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 8
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 5
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 238000005534 hematocrit Methods 0.000 claims 1
- 210000001995 reticulocyte Anatomy 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800102P | 2013-03-15 | 2013-03-15 | |
| US61/800,102 | 2013-03-15 | ||
| PCT/US2014/018743 WO2014149477A1 (en) | 2013-03-15 | 2014-02-26 | Methods for achieving therapeutically effective doses of anti-cd47 agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018201216A Division JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513640A JP2016513640A (ja) | 2016-05-16 |
| JP2016513640A5 true JP2016513640A5 (cg-RX-API-DMAC7.html) | 2017-03-30 |
| JP6426693B2 JP6426693B2 (ja) | 2018-11-21 |
Family
ID=51580621
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500441A Active JP6426693B2 (ja) | 2013-03-15 | 2014-02-26 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2018201216A Active JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2020084674A Active JP7007422B2 (ja) | 2013-03-15 | 2020-05-13 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2022001223A Active JP7246528B2 (ja) | 2013-03-15 | 2022-01-06 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2023039709A Active JP7562736B2 (ja) | 2013-03-15 | 2023-03-14 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018201216A Active JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2020084674A Active JP7007422B2 (ja) | 2013-03-15 | 2020-05-13 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2022001223A Active JP7246528B2 (ja) | 2013-03-15 | 2022-01-06 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2023039709A Active JP7562736B2 (ja) | 2013-03-15 | 2023-03-14 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US9623079B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3792285A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6426693B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN112245586A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2014238105B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2903773A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2970493T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2728066T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL241347B (cg-RX-API-DMAC7.html) |
| PT (1) | PT2970493T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014149477A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| HUE050958T2 (hu) | 2008-01-15 | 2021-01-28 | Univ Leland Stanford Junior | Akut mieloid leukémia õssejtek markerei |
| US11072655B2 (en) * | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| JP6572131B2 (ja) | 2012-12-12 | 2019-09-04 | バスキュロックス インコーポレイテッド | 治療用ｃｄ４７抗体 |
| CN112245586A (zh) * | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| EP3046627B1 (en) | 2013-09-18 | 2019-10-23 | The Board of Trustees of the Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| WO2016065245A1 (en) * | 2014-10-24 | 2016-04-28 | Incept, Llc | Extra luminal scaffold |
| RU2576614C1 (ru) * | 2015-01-19 | 2016-03-10 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "33 ЦЕНТРАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИСПЫТАТЕЛЬНЫЙ ИНСТИТУТ" Минобороны России | Способ поиска точки с дробным эффектом при определении эффективных доз веществ методом "одной точки" |
| ES2761861T3 (es) | 2015-01-21 | 2020-05-21 | Univ Leland Stanford Junior | Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas |
| ES2941387T3 (es) * | 2015-02-27 | 2023-05-22 | Univ Leland Stanford Junior | Terapia de combinación para el tratamiento de la ateroesclerosis |
| ES2881771T3 (es) | 2015-08-07 | 2021-11-30 | Alx Oncology Inc | Constructos que tienen un dominio de SIRP-alfa o variante del mismo |
| JP6885606B2 (ja) | 2015-09-18 | 2021-06-16 | アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. | 治療用ｃｄ４７抗体 |
| CA2999277A1 (en) | 2015-09-21 | 2017-03-30 | Surface Oncology, Inc. | Anti-cd47 antibodies and methods of use |
| WO2017100462A2 (en) | 2015-12-11 | 2017-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
| CA3011429A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| ES2909835T3 (es) * | 2016-04-15 | 2022-05-10 | Univ Leland Stanford Junior | Métodos para determinar y alcanzar dosis terapéuticamente efectivas de agentes anti-CD47 en el tratamiento del cáncer |
| US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| WO2017190148A1 (en) | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ４７併用療法 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| US10995152B2 (en) * | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| EP3589368A4 (en) | 2017-02-28 | 2021-03-24 | The Board of Trustees of the Leland Stanford Junior University | ANTIFIBROTIC ACTIVITY OF CD47 BLOCKING |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| PT3642242T (pt) | 2017-06-21 | 2024-04-16 | Univ Leland Stanford Junior | Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas |
| NZ761568A (en) | 2017-08-02 | 2022-11-25 | Phanes Therapeutics Inc | Anti-cd47 antibodies and uses thereof |
| WO2019079549A1 (en) | 2017-10-18 | 2019-04-25 | Forty Seven, Inc. | TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1 |
| AU2018351006B2 (en) | 2017-10-18 | 2024-08-29 | Forty Seven, LLC | Anti-CD47 agent-based ovarian cancer therapy |
| US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
| PT3752190T (pt) * | 2018-02-12 | 2022-11-18 | Forty Seven Inc | Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20 |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| PE20211491A1 (es) | 2018-09-27 | 2021-08-11 | Celgene Corp | PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| US20220119523A1 (en) * | 2019-02-08 | 2022-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
| CA3140639A1 (en) * | 2019-05-24 | 2020-12-03 | Forty Seven, Inc. | Regimes for co-administration of immunotherapeutic agents against c-kit and cd47 |
| JP7710997B2 (ja) | 2019-05-31 | 2025-07-22 | エーエルエックス オンコロジー インコーポレイテッド | 免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法 |
| CN114206912B (zh) * | 2019-06-07 | 2025-02-11 | Alx肿瘤生物技术公司 | 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂 |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies specific for cd47, pd-l1, and uses thereof |
| AU2021356708A1 (en) * | 2020-10-09 | 2023-05-11 | Sana Biotechnology, Inc. | METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT |
| EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| IL308400A (en) | 2021-05-13 | 2024-01-01 | Alx Oncology Inc | Combined therapies for cancer treatment |
| EP4376856A1 (en) * | 2021-07-28 | 2024-06-05 | Actinium Pharmaceuticals, Inc. | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20240043846A1 (en) | 2021-11-19 | 2024-02-08 | Kist (Korea Institute Of Science And Technology) | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell |
| KR20240131437A (ko) * | 2022-01-10 | 2024-08-30 | 키닉사 파마슈티컬스, 게엠베하 | 이식 거부반응을 치료하거나 이의 위험을 감소시키는 방법 |
| EP4479084A1 (en) | 2022-02-14 | 2024-12-25 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| CN120202222A (zh) | 2022-11-16 | 2025-06-24 | 勃林格殷格翰国际有限公司 | 抗SIRPa抗体的疗效预测性生物标志物 |
| CN120344257A (zh) | 2022-12-09 | 2025-07-18 | 美国辉瑞有限公司 | Cd47阻断剂和抗cd20/抗cd3双特异性抗体组合疗法 |
| KR20250116736A (ko) | 2022-12-09 | 2025-08-01 | 화이자 인코포레이티드 | Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| US7282556B2 (en) * | 2001-05-15 | 2007-10-16 | Emory University | Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47 |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US20070113297A1 (en) | 2005-09-13 | 2007-05-17 | Yongguang Yang | Methods and compositions for inhibition of immune responses |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2573112A1 (en) | 2007-10-11 | 2013-03-27 | The Hospital For Sick Children | Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| CN101456911A (zh) * | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
| HUE050958T2 (hu) | 2008-01-15 | 2021-01-28 | Univ Leland Stanford Junior | Akut mieloid leukémia õssejtek markerei |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| EP4134095A1 (en) | 2009-09-15 | 2023-02-15 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| US9151760B2 (en) * | 2009-09-29 | 2015-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| HUE060541T2 (hu) | 2010-05-14 | 2023-03-28 | Univ Leland Stanford Junior | Humanizált és kiméra monoklonális CD47 elleni ellenanyagok |
| PT2804617T (pt) * | 2012-01-17 | 2020-09-10 | Univ Leland Stanford Junior | Reagentes sirp-alfa de alta afinidade |
| SMT201900453T1 (it) * | 2012-02-06 | 2019-11-13 | Inhibrx Inc | Anticorpi anti cd47 e relativi metodi d'uso |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| KR102276974B1 (ko) * | 2013-02-06 | 2021-07-13 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
-
2014
- 2014-02-26 CN CN202010960541.4A patent/CN112245586A/zh active Pending
- 2014-02-26 PT PT14768797T patent/PT2970493T/pt unknown
- 2014-02-26 AU AU2014238105A patent/AU2014238105B2/en active Active
- 2014-02-26 ES ES14768797T patent/ES2728066T3/es active Active
- 2014-02-26 CN CN202210327266.1A patent/CN114917336A/zh active Pending
- 2014-02-26 JP JP2016500441A patent/JP6426693B2/ja active Active
- 2014-02-26 EP EP20201319.9A patent/EP3792285A1/en not_active Ceased
- 2014-02-26 DK DK14768797.4T patent/DK2970493T3/da active
- 2014-02-26 CA CA2903773A patent/CA2903773A1/en active Pending
- 2014-02-26 EP EP14768797.4A patent/EP2970493B1/en active Active
- 2014-02-26 EP EP19166334.3A patent/EP3536709A1/en active Pending
- 2014-02-26 US US14/769,069 patent/US9623079B2/en active Active
- 2014-02-26 WO PCT/US2014/018743 patent/WO2014149477A1/en not_active Ceased
- 2014-02-26 CN CN201480015159.9A patent/CN105189556A/zh active Pending
-
2015
- 2015-09-09 IL IL241347A patent/IL241347B/en active IP Right Grant
-
2017
- 2017-02-02 US US15/423,325 patent/US10301387B2/en active Active
-
2018
- 2018-10-25 JP JP2018201216A patent/JP6704974B2/ja active Active
-
2019
- 2019-01-17 AU AU2019200294A patent/AU2019200294B2/en active Active
- 2019-04-04 US US16/375,238 patent/US11104731B2/en active Active
-
2020
- 2020-05-13 JP JP2020084674A patent/JP7007422B2/ja active Active
- 2020-11-17 AU AU2020270485A patent/AU2020270485B2/en active Active
- 2020-11-23 US US17/102,183 patent/US11136391B2/en active Active
-
2021
- 2021-08-12 US US17/401,046 patent/US12258399B2/en active Active
-
2022
- 2022-01-06 JP JP2022001223A patent/JP7246528B2/ja active Active
- 2022-05-02 US US17/734,904 patent/US11603404B2/en active Active
- 2022-05-02 US US17/734,949 patent/US11518806B2/en active Active
-
2023
- 2023-02-03 US US18/164,252 patent/US12258403B2/en active Active
- 2023-03-14 JP JP2023039709A patent/JP7562736B2/ja active Active
-
2024
- 2024-08-20 AU AU2024210996A patent/AU2024210996A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513640A5 (cg-RX-API-DMAC7.html) | ||
| CY1122143T1 (el) | Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα | |
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| PE20160953A1 (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2018512391A5 (cg-RX-API-DMAC7.html) | ||
| JP2012529021A5 (cg-RX-API-DMAC7.html) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2019532047A5 (cg-RX-API-DMAC7.html) | ||
| EA201391017A1 (ru) | Способы и готовые лекарственные формы для лечения болезни альцгеймера | |
| JP2019515899A5 (cg-RX-API-DMAC7.html) | ||
| RU2019109464A (ru) | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
| JP2018508516A5 (cg-RX-API-DMAC7.html) | ||
| GB2496794A (en) | Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2016519107A5 (cg-RX-API-DMAC7.html) | ||
| RU2016151179A (ru) | Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| EA201791898A1 (ru) | Новые антитела, связывающиеся с tfpi, и содержащая их композиция | |
| JP2015511226A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530706A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533220A5 (cg-RX-API-DMAC7.html) |